JP6918007B2 - 組合せプレバイオティクス及びプロバイオティクス組成物 - Google Patents
組合せプレバイオティクス及びプロバイオティクス組成物 Download PDFInfo
- Publication number
- JP6918007B2 JP6918007B2 JP2018543445A JP2018543445A JP6918007B2 JP 6918007 B2 JP6918007 B2 JP 6918007B2 JP 2018543445 A JP2018543445 A JP 2018543445A JP 2018543445 A JP2018543445 A JP 2018543445A JP 6918007 B2 JP6918007 B2 JP 6918007B2
- Authority
- JP
- Japan
- Prior art keywords
- fermentation
- lactic acid
- seaweed
- fermentation composition
- algae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 257
- 239000006041 probiotic Substances 0.000 title claims description 12
- 235000018291 probiotics Nutrition 0.000 title claims description 12
- 235000013406 prebiotics Nutrition 0.000 title claims description 10
- 238000000855 fermentation Methods 0.000 claims description 241
- 230000004151 fermentation Effects 0.000 claims description 236
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 222
- 239000004310 lactic acid Substances 0.000 claims description 111
- 235000014655 lactic acid Nutrition 0.000 claims description 111
- 241001474374 Blennius Species 0.000 claims description 93
- 241000894006 Bacteria Species 0.000 claims description 79
- 241000219198 Brassica Species 0.000 claims description 66
- 241000195493 Cryptophyta Species 0.000 claims description 54
- 241000124008 Mammalia Species 0.000 claims description 50
- 201000010099 disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 239000000047 product Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 235000011331 Brassica Nutrition 0.000 claims description 21
- 241000186660 Lactobacillus Species 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 21
- 206010020751 Hypersensitivity Diseases 0.000 claims description 20
- 241000192001 Pediococcus Species 0.000 claims description 20
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 20
- 206010016256 fatigue Diseases 0.000 claims description 20
- 229940039696 lactobacillus Drugs 0.000 claims description 20
- 206010010774 Constipation Diseases 0.000 claims description 19
- 241000194036 Lactococcus Species 0.000 claims description 19
- 208000035143 Bacterial infection Diseases 0.000 claims description 18
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 18
- 206010012735 Diarrhoea Diseases 0.000 claims description 17
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 230000000968 intestinal effect Effects 0.000 claims description 16
- 241000894007 species Species 0.000 claims description 14
- 230000007815 allergy Effects 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 12
- 230000006641 stabilisation Effects 0.000 claims description 12
- 238000011105 stabilization Methods 0.000 claims description 12
- 208000034189 Sclerosis Diseases 0.000 claims description 11
- 208000026935 allergic disease Diseases 0.000 claims description 11
- 241000194033 Enterococcus Species 0.000 claims description 10
- 206010067125 Liver injury Diseases 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 208000008035 Back Pain Diseases 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 5
- 241000199919 Phaeophyceae Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 239000013066 combination product Substances 0.000 claims description 4
- 229940127555 combination product Drugs 0.000 claims description 4
- 229920003354 Modic® Polymers 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 231100000234 hepatic damage Toxicity 0.000 claims description 3
- 230000008818 liver damage Effects 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims 2
- 208000022555 Genital disease Diseases 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 description 112
- 239000000463 material Substances 0.000 description 109
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 94
- 240000002791 Brassica napus Species 0.000 description 80
- 239000000126 substance Substances 0.000 description 67
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 62
- 125000004383 glucosinolate group Chemical group 0.000 description 43
- 235000012000 cholesterol Nutrition 0.000 description 42
- 108010074051 C-Reactive Protein Proteins 0.000 description 37
- 102100032752 C-reactive protein Human genes 0.000 description 37
- 230000009467 reduction Effects 0.000 description 30
- BPPVOXVSMSXBEI-UHFFFAOYSA-N dihydrosinapic acid Natural products COC1=CC(CCC(O)=O)=CC(OC)=C1O BPPVOXVSMSXBEI-UHFFFAOYSA-N 0.000 description 29
- DZRJZDQAGMZGGA-UHFFFAOYSA-L 3-(1,3-dioxoisoindol-2-yl)propyl-[6-[3-(1,3-dioxoisoindol-2-yl)propyl-dimethylazaniumyl]hexyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].O=C1C2=CC=CC=C2C(=O)N1CCC[N+](C)(C)CCCCCC[N+](C)(C)CCCN1C(=O)C2=CC=CC=C2C1=O DZRJZDQAGMZGGA-UHFFFAOYSA-L 0.000 description 24
- 235000013305 food Nutrition 0.000 description 23
- 241000255969 Pieris brassicae Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 238000008214 LDL Cholesterol Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 17
- 108010010234 HDL Lipoproteins Proteins 0.000 description 15
- 102000015779 HDL Lipoproteins Human genes 0.000 description 15
- 241000191940 Staphylococcus Species 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 14
- 230000006378 damage Effects 0.000 description 14
- 201000004681 Psoriasis Diseases 0.000 description 13
- 230000000087 stabilizing effect Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000002054 inoculum Substances 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 12
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 241000191996 Pediococcus pentosaceus Species 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 239000000306 component Substances 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 235000013311 vegetables Nutrition 0.000 description 11
- 241000193468 Clostridium perfringens Species 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 244000005709 gut microbiome Species 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 235000021109 kimchi Nutrition 0.000 description 10
- 241000194031 Enterococcus faecium Species 0.000 description 9
- 235000019779 Rapeseed Meal Nutrition 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 239000004456 rapeseed meal Substances 0.000 description 9
- 241000193403 Clostridium Species 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 240000007124 Brassica oleracea Species 0.000 description 7
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 7
- 206010042953 Systemic sclerosis Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000193163 Clostridioides difficile Species 0.000 description 6
- 240000006024 Lactobacillus plantarum Species 0.000 description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 6
- 241001466453 Laminaria Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000202223 Oenococcus Species 0.000 description 6
- 241000191998 Pediococcus acidilactici Species 0.000 description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 description 6
- 208000030961 allergic reaction Diseases 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 235000011293 Brassica napus Nutrition 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 5
- 239000003435 antirheumatic agent Substances 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- -1 fatty acid compound Chemical class 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 201000007235 gluten allergy Diseases 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 201000005671 spondyloarthropathy Diseases 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 241000193798 Aerococcus Species 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 4
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 4
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 235000012041 food component Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 3
- 235000006008 Brassica napus var napus Nutrition 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000206594 Carnobacterium Species 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 208000037384 Clostridium Infections Diseases 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 201000000628 Gas Gangrene Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 241000983746 Saccharina latissima Species 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000003529 anticholesteremic agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 101710092462 Alpha-hemolysin Proteins 0.000 description 2
- 101710197219 Alpha-toxin Proteins 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 244000060924 Brassica campestris Species 0.000 description 2
- 235000005637 Brassica campestris Nutrition 0.000 description 2
- 235000003351 Brassica cretica Nutrition 0.000 description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 2
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 2
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 2
- 235000003343 Brassica rupestris Nutrition 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 101710124951 Phospholipase C Proteins 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002776 alpha toxin Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 206010028320 muscle necrosis Diseases 0.000 description 2
- 235000010460 mustard Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 235000012015 potatoes Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- DHEZNVNONLISRQ-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC(C(C)C(O)=O)=CC(OC)=C1O DHEZNVNONLISRQ-UHFFFAOYSA-N 0.000 description 1
- AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 description 1
- IKOKHHBZFDFMJW-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2-morpholin-4-ylethoxy)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCCN1CCOCC1 IKOKHHBZFDFMJW-UHFFFAOYSA-N 0.000 description 1
- VNPMDUDIDCXVCH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(3-piperazin-1-ylpropyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(CCCN2CCNCC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VNPMDUDIDCXVCH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010061430 Arthritis allergic Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 235000011303 Brassica alboglabra Nutrition 0.000 description 1
- 235000011302 Brassica oleracea Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000022453 Clostridium infectious disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010539 Congenital megacolon Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000008279 Dumping Syndrome Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000004592 Hirschsprung disease Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 241000194038 Lactococcus plantarum Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241001598113 Laminaria digitata Species 0.000 description 1
- 244000172809 Leuconostoc cremoris Species 0.000 description 1
- 235000017632 Leuconostoc cremoris Nutrition 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037884 Rash pruritic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241000207194 Vagococcus Species 0.000 description 1
- 235000002096 Vicia faba var. equina Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 201000002898 anismus Diseases 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 235000005489 dwarf bean Nutrition 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- DNDNWOWHUWNBCK-NMIPTCLMSA-N indolylmethylglucosinolate Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S\C(=N\OS(O)(=O)=O)CC1=CNC2=CC=CC=C12 DNDNWOWHUWNBCK-NMIPTCLMSA-N 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/413—Acidilactici
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/427—Pentosaceus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
Description
(a)本発明による発酵組成物、又は本発明による物質と;
(b)1種又は複数の薬物と
を含む組み合わせ製品を提供することである。
(i)植物材料を提供する工程と;
(ii)1種又は複数の乳酸菌株を提供する工程と;
(iii)工程a)で提供された植物材料を、工程b)で提供された1種又は複数の乳酸菌株と組み合わせることによって、植物材料を発酵に供する工程と;
(iv)pH値が5.0未満であり、
(a)乾物ベースで少なくとも2μmol/g以上の総グルコシノレート含量、及び/又は
(b)少なくとも1種の植物材料中に自然に存在する少なくとも10%(w/w)のグルコシノレート
を有する発酵組成物が提供されるまで、発酵を続ける工程と、を含む方法を提供することである。
(i)植物材料を提供する工程と;
(ii)1種又は複数の乳酸菌株を提供する工程と;
(iii)工程a)で提供された植物材料を、工程b)で提供された1種又は複数の乳酸菌株と組み合わせることによって、植物材料を発酵に供する工程と;
(iv)pH値が5.0未満であり、
(a)乾物ベースで少なくとも2μmol/g以上の総グルコシノレート含量、及び/又は
(b)少なくとも1種の植物材料中に自然に存在する少なくとも10%(w/w)のグルコシノレート
を有する発酵組成物が提供されるまで、発酵を続ける工程と、を含む方法に関する。
(a)本発明による発酵組成物又は本発明による物質と;
(b)1種又は複数の薬物と
を含む組み合わせ製品に関する。
グルテンアレルギーに罹患している2人の患者及び乳糖不耐性に罹患している1人の患者に、1日当たり約25gの実施例1で得られた発酵組成物を摂取させた。発酵組成物を摂取した後、患者のいずれも不快感もアレルギー反応も経験せず、3人の患者全員が制限なく食べることができた。1人の患者は発酵組成物の摂取を中止し、アレルギー反応が戻った。再び発酵組成物の接種を開始すると、再び患者は不快感もアレルギー反応も経験せず、再び制限なく食べることができた。
便秘に罹患している8人の患者に、約25gの単一用量の実施例1で得られた発酵組成物を摂取させた。1〜3時間後、全患者が便秘の軽減及び便通改善を経験した。
大腸菌(E.Coli)による細菌感染症に起因する下痢に罹患している1人の患者に、20gの単一用量の実施例1で得られた発酵組成物を摂取させた。2時間後、患者はより堅い便を得て、気分が良くなり始めた。10時間後に再び便が緩くなり、下痢の症状が戻った。患者は更に20gの実施例1で得られた発酵組成物を摂取し、患者は再びより堅い便を得て、気分が良くなった。
炎症性腸疾患(IBD)、クローン病に起因する下痢に罹患している2人の患者、及び炎症性腸疾患(IBD)、潰瘍性大腸炎に罹患している2人の患者は、伝統的な医療に反応しなかったが、彼らに15gの単一用量の実施例2で得られた発酵組成物を摂取させた。2時間後、患者はより堅い便を得て、胃の痛みが有意に少なくなり気分が良くなり始めた。
HLA B27関連脊椎関節炎、乾癬性関節炎に罹患している58歳の1人の患者は、4年半、抗TNFα薬、及びメトトレキサートによる治療等のDMARD治療(疾患修飾性抗リウマチ薬による治療)を含む通常の処方された治療を受けていた。
グラム陽性菌であるウェルシュ菌(Clostridium perfringens)に対する様々な組成物効果を比較する実験室実験を行った。3つの組成物を試験した:
2)本発明による組成物(植物材料がナタネであり、これを粉砕し、0.25g/mlの濃度で水に懸濁する)。固体を激しく撹拌した後、上清を試験に使用する)、
3)水を含む対照。
重度のざ瘡に罹患した1人の患者に、20gの単一用量の実施例1で得られた発酵組成物を摂取させた。14日の期間後、皮膚症状は完全に消失した。
植物抽出物中の潜在的差異及び生成物を同定するために、植物抽出物をQ−ToF質量分析計と連結した超高圧液体クロマトグラフィー(UHPLC−Q−ToF−MS)による非標的化メタボロミクス分析に供した。
発酵組み合わせ製品(ナタネと海藻)を分析すると、優勢なピークが以下の(負のモードにおける)「質量電荷比」(m/z)を有することが示された:
MS2質量=223.1694;87.0436;235.1666;224.1725;275.2005
保持時間:22.52分(設定条件下)
保持時間:11.86分(設定条件下)
保持時間11.86分(設定条件下)
本発明による発酵組成物のコレステロール及び肝損傷に対する効果を、2つの異なる品種の雌ブタ、1)ポーランドラージホワイト及び2)ポーランドランドレースで試験した。妊娠中雌ブタと泌乳中雌ブタの両方で試験を行った。
K1妊娠中:発酵組成物を含まない通常の飼料を与えられたポーランドラージホワイト雌ブタ。
K2妊娠中:発酵組成物を含まない通常の飼料を与えられたポーランドランドレース雌ブタ。
K1泌乳中:発酵組成物を含まない通常の飼料を与えられたポーランドラージホワイト雌ブタ。
K2泌乳中:発酵組成物を含まない通常の飼料を与えられたポーランドランドレース雌ブタ。
D1妊娠中:4%の実施例1で得られた発酵組成物を含む混合飼料を与えられたポーランドラージホワイト雌ブタ。
D2妊娠中:4%の実施例1で得られた発酵組成物を含む混合飼料を与えられたポーランドランドレース雌ブタ。
D1泌乳中:4%の実施例1で得られた発酵組成物を含む混合飼料を与えられたポーランドラージホワイト雌ブタ。
D2泌乳中:4%の実施例1で得られた発酵組成物を含む混合飼料を与えられたポーランドランドレース雌ブタ。
総コレステロール濃度
LDLコレステロール濃度
HDLコレステロール濃度
トリグリセリド濃度
AST濃度
ALT濃度
ALP濃度
総コレステロール、LDLコレステロール、HDLコレステロール、及びトリグリセリドを測定した結果を図4に示す。
AST、ALT、及びALPの濃度を測定した結果を以下の表1に示す。
国際公開第2013/029632号パンフレット
国際公開第2014/131422号パンフレット
国際公開第2014/206419号パンフレット
Jeong−Jeuら、Journal of Medicinal Food、18(6)2015、677〜684
Hyun Ju Kimら、J. Agric. Food Chem.、2007、55、10486〜10492
Jeong sook Nohら、British Journal of Nutrition;(2013)、109、17〜24
Ye−Rang Yunら、Journal of Medicinal Food、17(8)2014、886〜893
Claims (14)
- アブラナ属(Brassica)種;海藻又は藻類;及び1種又は複数の乳酸菌株を含み、前記海藻又は藻類が褐藻類であり、本質的にホモ発酵性工程により得られる、医薬品として使用するための発酵組成物。
- アブラナ属(Brassica)種と海藻又は藻類との組み合わせ;及び1種又は複数の乳酸菌株を含むみ、前記海藻又は藻類が褐藻類であり、本質的にホモ発酵性工程により得られる、哺乳動物における腸誘発疾患の治療、緩和、安定化、又は予防に使用するための発酵組成物。
- 前記哺乳動物における腸誘発疾患が、自己炎症性疾患;硬化症;アレルギー又は不耐性;便秘;腸内細菌叢の活性化;疲労、炎症、下痢;出生前後の乳児腸内細菌叢の刺激;炎症性腸疾患、細菌感染症、皮膚疾患、2型糖尿病、及び/又はX線で確認されるモディック変化(Modic change)(I及びII)を伴う又は伴わない背痛からなる群から選択され得る、請求項2に記載の発酵組成物。
- 自己炎症性疾患;硬化症;アレルギー又は不耐性;便秘;腸内細菌叢の活性化;疲労、炎症、下痢;出生前後の乳児腸内細菌叢の刺激;炎症性腸疾患、細菌感染症、皮膚疾患、2型糖尿病、及び/又はX線で確認されるモディック変化(Modic change)(I及びII)を伴う又は伴わない背痛の治療、緩和、安定化、又は予防に使用するための発酵組成物であって、アブラナ属(Brassica)種;海藻又は藻類;及び1種又は複数の乳酸菌株を含み、
前記海藻又は藻類が褐藻類であり、本質的にホモ発酵性工程により得られる、発酵組成物。 - アブラナ属(Brassica)種;海藻又は藻類;及び1種又は複数の乳酸菌株を含み、前記海藻又は藻類が褐藻類であり、本質的にホモ発酵性工程により得られる、血中コレステロール減少剤、トリグリセリド減少剤、肝損傷の減少、及び/又は高血圧低下剤として使用するための発酵組成物。
- 1種又は複数の他の薬物を伴うアジュバント製品である、請求項1〜5のいずれか1項に記載の発酵組成物。
- pH6.5未満のpH値を有する、請求項1〜6のいずれか1項に記載の発酵組成物。
- 少なくとも50mMの乳酸濃度を有する、請求項1〜7のいずれか1項に記載の発酵組成物。
- 前記1種又は複数の乳酸菌が、エンテロコッカス属、ラクトバチルス属、ペディオコッカス属及びラクトコッカス属、並びにこれらの組み合わせからなる群から選択される、請求項1〜8のいずれか1項に記載の発酵組成物。
- 前記本質的にホモ発酵性工程は、本質的にホモ乳酸発酵工程である、請求項1〜9のいずれか1項に記載の発酵組成物。
- 嫌気性発酵工程により得られる、請求項1〜10のいずれか1項に記載の発酵組成物。
- 前記アブラナ属(Brassica)種の含有量が少なくとも50%である、請求項1〜11のいずれか1項に記載の発酵組成物。
- プレバイオティクス及びプロバイオティクス組成物である、請求項1〜12のいずれか1項に記載の発酵組成物。
- (a)請求項1〜13のいずれか1項に記載の発酵組成物と;
(b)1種又は複数の薬物と
を含む、組み合わせ製品。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201500700 | 2015-11-08 | ||
DKPA201500700 | 2015-11-08 | ||
DKPA201600128 | 2016-02-29 | ||
DKPA201600128 | 2016-02-29 | ||
DKPA201600431 | 2016-07-20 | ||
DKPA201600431 | 2016-07-20 | ||
DKPA201600537 | 2016-09-14 | ||
DKPA201600537 | 2016-09-14 | ||
PCT/EP2016/076952 WO2017077139A1 (en) | 2015-11-08 | 2016-11-08 | Combined pre- and pro-biotic composition |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019500056A JP2019500056A (ja) | 2019-01-10 |
JP2019500056A5 JP2019500056A5 (ja) | 2019-12-19 |
JP6918007B2 true JP6918007B2 (ja) | 2021-08-11 |
Family
ID=57249812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018543445A Active JP6918007B2 (ja) | 2015-11-08 | 2016-11-08 | 組合せプレバイオティクス及びプロバイオティクス組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200164009A1 (ja) |
EP (1) | EP3370750A1 (ja) |
JP (1) | JP6918007B2 (ja) |
KR (1) | KR20180080256A (ja) |
CN (1) | CN108883143A (ja) |
AU (1) | AU2016348786B2 (ja) |
BR (1) | BR112018009192B1 (ja) |
CA (1) | CA3003775A1 (ja) |
RU (1) | RU2768499C2 (ja) |
WO (1) | WO2017077139A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018103808A1 (en) * | 2016-12-07 | 2018-06-14 | Vivox Aps | A fermented composition comprising a high content of one or more lactic acid bacterial strains and a method for making the composition and use thereof |
US20210177028A1 (en) * | 2018-08-20 | 2021-06-17 | Fermbiotics Holding ApS | Improved human food product |
CN109136131A (zh) * | 2018-08-27 | 2019-01-04 | 南昌大学 | 一株具有缓解结肠炎功效的鼠李糖乳杆菌及其应用 |
MX2021002844A (es) * | 2018-09-19 | 2021-07-15 | Fermentationexperts As | Proceso para controlar un proceso de fermentacion. |
WO2020058365A1 (en) * | 2018-09-19 | 2020-03-26 | Fermentationexperts A/S | Composition against resistant organisms (mrsa) |
TWI693072B (zh) * | 2018-12-14 | 2020-05-11 | 大漢酵素生物科技股份有限公司 | 含有硫苷化合物的抗癌組合物及其用途 |
WO2020207920A1 (en) * | 2019-04-06 | 2020-10-15 | Fermentationexperts A/S | Anti-inflammatory composition |
TWI766184B (zh) * | 2019-09-04 | 2022-06-01 | 歐斐生 | 一種植物乳桿菌及其製備植物性凝態優格、改善腸道菌相的用途 |
KR102662148B1 (ko) * | 2020-08-21 | 2024-05-02 | 주식회사 제노포커스 | 프리바이오틱스 또는 신바이오틱스를 유효성분으로 포함하는 면역증강용 조성물 |
WO2022140409A1 (en) | 2020-12-23 | 2022-06-30 | Church & Dwight Co., Inc. | Compositions and methods to increase production of isothiocyanates |
WO2024008597A1 (en) * | 2022-07-04 | 2024-01-11 | Alfasigma S.P.A. | Fermentation product for the treatment of inflammatory diseases |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0205647D0 (en) * | 2002-03-11 | 2002-04-24 | Danisco Cultor Niebull Gmbh | Method of improving food fermentation procedures |
FI116878B (fi) * | 2003-02-21 | 2006-03-31 | Maa Ja Elintarviketalouden Tut | Glukosinolaattien entsymaattisen hajottamisen ohjaaminen maitohappobakteerin avulla |
DK1716258T3 (da) * | 2004-04-15 | 2010-06-07 | Chr Hansen As | En metode til reducering af indholdet af patogene organismer fundet i fødevarer |
JP2006298871A (ja) * | 2005-04-25 | 2006-11-02 | Otaka Koso Kk | 植物エキス発酵液の方法、その方法による植物エキス発酵液並びに哺乳動物の治療方法 |
JP5626970B2 (ja) * | 2010-07-05 | 2014-11-19 | 株式会社 越後薬草 | ミネラル吸収促進剤 |
DE102012100466A1 (de) * | 2011-04-21 | 2012-10-25 | Hochschule Fulda | Anlage und Verfahren zur Herstellung eines proteinreichen fettarmen pflanzlichen Produktes aus einem Presskuchen und Verwendung eines proteinreichen fettarmen pflanzlichen Produktes |
DK177482B1 (en) | 2011-09-02 | 2013-07-08 | Fermentationexperts As | Method of manufacturing a fermented dry feed using a spin flash dryer |
JP5571650B2 (ja) * | 2011-12-27 | 2014-08-13 | 農業生産法人株式会社 熱帯資源植物研究所 | 非アルコール性脂肪性肝疾患および/または非アルコール性脂肪肝炎の治療薬 |
JP5390589B2 (ja) * | 2011-12-27 | 2014-01-15 | 農業生産法人株式会社 熱帯資源植物研究所 | 血管新生阻害剤 |
WO2014131422A2 (en) | 2013-02-28 | 2014-09-04 | Fermentationexperts A/S | Fermented rapeseed feed ingredient |
CN103190626B (zh) * | 2013-04-17 | 2014-12-03 | 肖天存 | 治疗口腔溃疡的果蔬食品及其制备方法 |
CA2916554C (en) * | 2013-06-28 | 2021-09-21 | Fermentationexperts A/S | Compositions comprising fermented seaweed and/or algae |
CN104543811B (zh) * | 2013-10-21 | 2018-05-15 | 广州博能生物科技有限公司 | 提高免疫力的天然复合粉及其制备方法和应用 |
CN104273404A (zh) * | 2014-10-10 | 2015-01-14 | 安徽省农业科学院畜牧兽医研究所 | 一种微生物固态发酵菜籽饼粕脱毒的方法 |
-
2016
- 2016-11-08 RU RU2018121036A patent/RU2768499C2/ru active
- 2016-11-08 AU AU2016348786A patent/AU2016348786B2/en active Active
- 2016-11-08 CA CA3003775A patent/CA3003775A1/en active Pending
- 2016-11-08 CN CN201680065161.6A patent/CN108883143A/zh active Pending
- 2016-11-08 JP JP2018543445A patent/JP6918007B2/ja active Active
- 2016-11-08 KR KR1020187015036A patent/KR20180080256A/ko not_active Application Discontinuation
- 2016-11-08 WO PCT/EP2016/076952 patent/WO2017077139A1/en active Application Filing
- 2016-11-08 BR BR112018009192-8A patent/BR112018009192B1/pt active IP Right Grant
- 2016-11-08 EP EP16791604.8A patent/EP3370750A1/en active Pending
- 2016-11-08 US US15/774,479 patent/US20200164009A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20180080256A (ko) | 2018-07-11 |
BR112018009192B1 (pt) | 2021-09-14 |
CA3003775A1 (en) | 2017-05-11 |
US20200164009A1 (en) | 2020-05-28 |
CN108883143A (zh) | 2018-11-23 |
EP3370750A1 (en) | 2018-09-12 |
RU2018121036A (ru) | 2019-12-09 |
AU2016348786A1 (en) | 2018-05-24 |
BR112018009192A2 (pt) | 2018-11-06 |
JP2019500056A (ja) | 2019-01-10 |
BR112018009192A8 (pt) | 2019-02-26 |
WO2017077139A1 (en) | 2017-05-11 |
RU2768499C2 (ru) | 2022-03-24 |
RU2018121036A3 (ja) | 2020-03-04 |
AU2016348786B2 (en) | 2023-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6918007B2 (ja) | 組合せプレバイオティクス及びプロバイオティクス組成物 | |
Alagawany et al. | Potential role of important nutraceuticals in poultry performance and health-A comprehensive review | |
Ahmed et al. | Effects of dietary natural and fermented herb combination on growth performance, carcass traits and meat quality in grower-finisher pigs | |
JP4199009B2 (ja) | 皮膚用の食事 | |
JP6012111B2 (ja) | 動物用飼料添加物 | |
Cai et al. | Effects of dietary gallic acid on growth performance, diarrhea incidence, intestinal morphology, plasma antioxidant indices, and immune response in weaned piglets | |
EP3551207A1 (en) | A fermented composition comprising a high content of one or more lactic acid bacterial strains and a method for making the composition and use thereof | |
Bontempo et al. | Administration of a novel plant extract product via drinking water to post-weaning piglets: effects on performance and gut health | |
Tolve et al. | Encapsulation of bioactive compounds for the formulation of functional animal feeds: The biofortification of derivate foods | |
Jiang et al. | Influence of a blend of essential oils and an enzyme combination on growth performance, microbial counts, ileum microscopic anatomy and the expression of inflammatory mediators in weaned piglets following an Escherichia coli infection | |
JP2022517578A (ja) | ペディオコッカスイノピナタスを含む退行性脳疾患の予防、改善又は治療用組成物 | |
WO2018050739A1 (en) | Kimchi based on a rape species | |
Ghasemi-Sadabadi et al. | Determining tolerance of Japanese quail to different dietary fat peroxidation values by supplementation with Rosemary and Aloe Vera on performance and meat quality | |
Yousaf et al. | A review of probiotic applications in poultry: improving immunity and having beneficial effects on production and health | |
US20210307359A1 (en) | Improved animal feed product | |
Castellini et al. | Feeding fresh chicory (Chicoria intybus) to young rabbits: Performance, development of gastro-intestinal tract and immune functions of appendix and Peyer's patch | |
Liu et al. | From probiotics to postbiotics: Concepts and applications | |
Yang et al. | Dietary Litsea cubeba essential oil supplementation improves growth performance and intestinal health of weaned piglets | |
Long et al. | Effects of dietary Forsythia suspensa extract supplementation to lactating sows and nursery pigs on post-weaning performance, antioxidant capacity, nutrient digestibility, immunoglobulins, and intestinal health | |
Abbas et al. | An update on the promising role of organic acids in broiler and layer production | |
Nopparatmaitree et al. | Effect of trimmed asparagus by-products supplementation in broiler diets on performance, nutrients digestibility, gut ecology, and functional meat production | |
Jarupan et al. | Effect of colistin and liquid methionine with capsaicin supplementation in diets on growth performance and intestinal morphology of nursery pigs | |
JP2023535821A (ja) | エンドカンナビノイドシステムを調節することで炎症性または機能性腸障害を治療するための、チモールおよびアミノ酸を含む組成物 | |
Maito et al. | Simultaneous feeding of calcium butyrate and tannin extract decreased the incidence of diarrhea and proinflammatory markers in weaned piglets | |
Sarfo et al. | Effect of direct-fed microbial addition in guinea fowl (Numida meleagris) diets on performance and health responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210622 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210720 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6918007 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |